Tags

Type your tag names separated by a space and hit enter

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Antimicrob Agents Chemother. 2012 Mar; 56(3):1613-5.AA

Abstract

MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were >8,192, 8,192, and 4 μg/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were >8,192 μg/ml, 1,024 μg/ml, and 1,024 μg/ml, respectively. The CB-183,315 MIC(90) for Clostridium difficile was 0.5 μg/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile.

Links

Publisher Full Text
ncbi.nlm.nih.gov
aac.asm.org
PMC Free PDF

Authors+Show Affiliations

Citron DM
RM Alden Research Lab, Culver City, California, USA. d.m.citron@att.net
Tyrrell KL
No affiliation info available
Merriam CV
No affiliation info available
Goldstein EJ
No affiliation info available

MeSH

Anti-Bacterial AgentsBacteria, AnaerobicClostridioides difficileEnterobacteriaceaeEnterobacteriaceae InfectionsEnterocolitis, PseudomembranousHumansIntestinesLipopeptidesMetronidazoleMicrobial Sensitivity TestsPeptides, CyclicVancomycin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22183166

Citation

Citron, Diane M., et al. "In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole Against 556 Strains of Clostridium Difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species." Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, 2012, pp. 1613-5.
Citron DM, Tyrrell KL, Merriam CV, et al. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother. 2012;56(3):1613-5.
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. (2012). In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrobial Agents and Chemotherapy, 56(3), 1613-5. https://doi.org/10.1128/AAC.05655-11
Citron DM, et al. In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole Against 556 Strains of Clostridium Difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species. Antimicrob Agents Chemother. 2012;56(3):1613-5. PubMed PMID: 22183166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. AU - Citron,Diane M, AU - Tyrrell,Kerin L, AU - Merriam,C Vreni, AU - Goldstein,Ellie J C, Y1 - 2011/12/19/ PY - 2011/12/21/entrez PY - 2011/12/21/pubmed PY - 2012/8/25/medline SP - 1613 EP - 5 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 56 IS - 3 N2 - MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were >8,192, 8,192, and 4 μg/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were >8,192 μg/ml, 1,024 μg/ml, and 1,024 μg/ml, respectively. The CB-183,315 MIC(90) for Clostridium difficile was 0.5 μg/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/22183166/In_vitro_activities_of_CB_183315_vancomycin_and_metronidazole_against_556_strains_of_Clostridium_difficile_445_other_intestinal_anaerobes_and_56_Enterobacteriaceae_species_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=22183166 DB - PRIME DP - Unbound Medicine ER -